~~<i id='D1E01A1397'><strike id='D1E01A1397'><tt id='D1E01A1397'><pre id='D1E01A1397'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：fashion 2025-09-02 08:13:22 - browse：9

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： STAT Summit: How a Chicago ER doctor tackles gun violence

entertainment

knowledge

leisure time

focus

entertainment

hotspot

AbdullahPratt,anemergencymedicinephysician,speaksatthe2023STATSummitinBoston.STATAbdullahPrattwasonl

WSS

Eli Lilly expects to double planned employment in Boston center

Medicare solvency divides Republicans at the presidential debate

Removing probiotics from the NICU could threaten preemies' health

FDA gives detailed accounting of AI

The new shift in health care is toward less care

White House calls on federal agencies to crack down on AI abuses

focus

Wikipedia

entertainment

Hollywood unions extend contract negotiations for actors

Solve the antibiotic resistance crisis with preventive drugs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Cancer drug shortages should be causing more outrage

10 million people disenrolled from Medicaid over past six months

Medical records are filled with copy

Medicare solvency divides Republicans at the presidential debate

BioMarin wins approval for gene therapy to treat hemophilia A

FDA gives detailed accounting of AI

knowledge

Abortion clinic in Cancun will cater to Americans

Senate panel clears PBM, hopsital reforms

Study: New antibiotic targets gonorrhea as well as last existing drug

Will Ozempic

CEOs share strategies for surviving biotech slump

The explosion of genetic testing requires a new approach

leisure time

focus

entertainment

hotspot